Dario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced a peer-reviewed JMIR Cardio study (Dec 4, 2025) showing that data-driven digital nudges from its platform were associated with sustained blood pressure (BP) improvements in real-world users.

Key findings: users with high BP saw a larger monthly systolic BP reduction after three months (B = –2.09; P < .001) versus propensity-matched controls (B = –1.06; P = .007); users with higher lifestyle activity achieved greater reduction (B = –5.27; P < .001). 59% of Dario clients use its cardio-metabolic suite.

Positive

• Systolic BP decline of B = –2.09 at three months versus baseline
• Control comparison showed smaller reduction (B = –1.06; P = .007)
• Greater benefit for active users: B = –5.27 in systolic BP
• Broad client reach: 59% of clients use cardio-metabolic suite

Negative

• None.

News Market Reaction

+1.27%

1 alert

+1.27% News Effect

On the day this news was published, DRIO gained 1.27%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

U.S. hypertension population: 120 million people Client hypertension focus: 59% of Dario clients High-BP cohort reduction: B = –2.09 +5 more

8 metrics

U.S. hypertension population 120 million people CDC estimate cited in article

Client hypertension focus 59% of Dario clients Leverage cardio-metabolic suite for hypertension management

High-BP cohort reduction B = –2.09 Monthly average systolic BP change at 3 months, intervention group

High-BP cohort P-value P < .001 Statistical significance for intervention group BP reduction

Control BP reduction B = –1.06 Monthly average systolic BP change at 3 months, control group

Control P-value P = .007 Statistical significance for control group BP reduction

High activity BP change B = –5.27 Systolic BP change among users with higher lifestyle activity

High activity P-value P < .001 Statistical significance for high-activity users’ BP reduction

Market Reality Check

Price: $12.44 Vol: Volume 36,333 is 22% abov...

normal vol

$12.44 Last Close

Volume Volume 36,333 is 22% above the 20-day average of 29,733. normal

Technical Price $12.76 is trading slightly below the 200-day MA $12.86, near a key trend level.

Peers on Argus

DRIO gained 4.11% with modestly elevated volume while close peers were mixed (e....

1 Up

DRIO gained 4.11% with modestly elevated volume while close peers were mixed (e.g., HCTI -1.6%, MGRX +2.73%, VSEE -1.03%). Momentum scanner showed only BEAT up 5.65%, suggesting today’s move was stock-specific rather than a broad sector rotation.

Common Catalyst Only one peer, VSEE, reported same-day news related to telehealth operations, indicating no broad, shared news catalyst across the group.

Historical Context

5 past events · Latest: Dec 09 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Private placement	Negative	+0.1%	Announced $17.5M private placement of 2.7M shares and equivalents.
Dec 04	Clinical study data	Positive	+1.3%	JMIR Cardio study showed digital nudges improved blood pressure outcomes.
Dec 02	Commercial update	Positive	+0.8%	Reported 79 new clients YTD, surpassing 2025 target by 98%.
Nov 24	Health economics data	Positive	-7.2%	JMIR study showed cost savings and lower utilization in type 2 diabetes.
Nov 13	Quarterly earnings	Neutral	-15.6%	Q3 2025 results highlighted ARR shift, strong margins, and cash details.

Pattern Detected

Recent positive clinical and commercial updates often saw modest gains, while some strong data and earnings events coincided with notable drawdowns, indicating mixed alignment between fundamentals and price reactions.

Recent Company History

Over the last month, DarioHealth reported several milestones. On Nov 13, Q3 2025 results showed lower revenue but highlighted higher-margin ARR growth and a $69M 2026 pipeline. Subsequent JMIR publications on Nov 24 and Dec 04 detailed real-world cost savings and sustained blood pressure benefits from its digital platform. On Dec 02, the company disclosed 79 new clients year-to-date, far exceeding its annual target. A September private placement and related resale registration added to the capital and regulatory backdrop for today’s study results.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-20

An effective S-3 shelf dated Oct 20, 2025 registers up to 2,713,180 shares for resale by existing holders, including common shares and pre-funded warrant shares. The company will not receive proceeds from these secondary sales but bears registration costs. The shelf runs through Oct 20, 2028 with 0 recorded usages to date.

Market Pulse Summary

This announcement highlights peer-reviewed evidence that DarioHealth’s data-driven digital nudges pr...

Analysis

This announcement highlights peer-reviewed evidence that DarioHealth’s data-driven digital nudges produced sustained improvements in systolic blood pressure, especially among highly engaged users. It reinforces prior JMIR publications and recent commercial updates showing broad adoption of its cardiometabolic suite. Investors may focus on how such outcomes support client retention, future contracts, and real-world validation. Monitoring subsequent earnings, additional studies, and updates around registered share resales could help contextualize the platform’s trajectory.

Key Terms

hypertension, systolic blood pressure, propensity-matched control group, retrospective real-world study, +3 more

7 terms

hypertension medical

"can meaningfully reduce blood pressure in individuals with hypertension – and help"

Hypertension is a condition where blood pressure in the arteries remains consistently high, making the heart work harder than normal to pump blood through the body. For investors, it can signal underlying health issues that might lead to increased medical costs or decreased productivity, potentially affecting a company's stability or the overall economy. Think of it as a warning sign of ongoing strain within a system that needs careful monitoring.

systolic blood pressure medical

"reduction in monthly average systolic blood pressure three months after the"

Systolic blood pressure is the top number in a blood pressure reading, measuring the pressure in your arteries when your heart beats and pumps blood. It indicates how forcefully the heart pushes blood through the body. For investors, it can symbolize the maximum stress or intensity in a system, helping to assess overall health risks or stability.

propensity-matched control group technical

"messages to a propensity-matched control group.According to the CDC"

A propensity-matched control group is a set of individuals or items selected to resemble a target group in key characteristics, ensuring fair comparisons. For investors, this helps determine whether observed effects are truly due to a specific factor or just differences between groups, much like comparing two similar groups of people to see if a particular intervention makes a difference. This approach improves the accuracy of conclusions about cause and effect.

retrospective real-world study technical

"Targeting Users With High Blood Pressure Events: Retrospective Real-World Study"

A retrospective real-world study analyzes existing data collected during routine medical care—such as electronic health records, insurance claims, or registries—to examine how a drug, device, or treatment performed in everyday practice. Investors care because these studies can reveal safety signals, effectiveness outside tightly controlled trials, and real-world uptake or cost impacts that influence regulatory decisions, reimbursement, and commercial prospects—similar to reviewing past receipts to judge a product’s real-world performance.

cardiovascular medical

"move the needle on key cardiovascular health outcomes," said Dr."

Relating to the heart and the network of blood vessels that pump and carry blood through the body — like the body’s engine and plumbing working together. Investors pay attention because conditions, treatments, devices, and drugs tied to this system drive large health care spending, regulatory reviews, and market demand; breakthroughs, safety issues, or trial results can quickly change a company’s revenue prospects and stock value.

digital health technical

"Dario's digital health platform are associated with significant and"

Digital health involves the use of technology, such as apps, wearable devices, and online platforms, to monitor, manage, and improve people's health and healthcare. For investors, it represents a growing industry that combines healthcare with digital innovation, offering new ways to deliver medical services and track wellness, which can lead to advancements in patient care and potential business opportunities.

behavior-informed technical

"belief that personalized, behavior-informed digital interventions – not just"

Behavior-informed describes decisions, designs or policies shaped by observed human behavior and psychological insights rather than only theory or assumptions. Think of it as using what people actually do—like how customers respond to price changes or how patients follow instructions—to tailor products, communications or regulations. Investors care because behavior-informed approaches can improve adoption, predictability and outcomes, reducing execution risk much like tuning a recipe to match diners’ real tastes.

AI-generated analysis. Not financial advice.

Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes

Data-driven engagement translates to lower health risks and downstream cost savings for Dario clients

Results highlight Dario's ability to deliver lasting impact and further cement the Company's position as a proven leader in evidence-based digital care   

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced publication of a new peer-reviewed study in JMIR Cardio demonstrating that data-driven nudges delivered via Dario's digital health platform are associated with significant and sustainable improvements in blood pressure ("BP") outcomes.

The study, titled "The Impact of Digital Intervention Messages Targeting Users With High Blood Pressure Events: Retrospective Real-World Study," analyzed real-world BP data from platform users whose health was tracked over time, comparing a cohort that received digital intervention messages to a propensity-matched control group.

According to the CDC, nearly 120 million people in the U.S. live with hypertension, a major public health challenge that has been identified as the leading preventable risk factor for premature death. 59% of Dario's clients today leverage its cardio-metabolic suite to support members in managing hypertension. 

Key findings were that among users with high BP (high-BP cohort), those receiving digital nudges experienced a statistically significant reduction in monthly average systolic blood pressure three months after the intervention (B = –2.09; P < .001), compared to a smaller reduction in the control group (B = –1.06; P = .007).  Users reporting higher lifestyle activity levels further achieved greater systolic blood pressure reduction (B = –5.27; P < .001), underscoring the additive benefit of behavioral engagement in conjunction with digital nudges.

This research provides important real-world clinical evidence that personalized, data-driven digital interventions can meaningfully reduce blood pressure in individuals with hypertension – and help maintain healthy BP levels in individuals without overt hypertension. The fact that BP improvements persisted over time after the initial intervention shows that digital nudges via Dario's platform are not merely momentary triggers, but instead can support sustained, long-term management of hypertension.

"This new study represents strong clinical evidence that data-driven digital nudges – when delivered reliably via a robust platform – can move the needle on key cardiovascular health outcomes," said Dr. Omar Manejwala, Chief Medical Officer at Dario. "Indeed, for employers, payers and health systems evaluating digital health , BP control and long-term sustainability are critical – and we believe that these data show Dario's approach delivers both."

"The findings reinforce Dario's belief that personalized, behavior-informed digital interventions – not just passive monitoring – are essential to achieving meaningful clinical impact," added Yifat Hershcovitz, PhD, Vice President of Clinical & Scientific Affairs at DarioHealth.

For employers and healthcare clients, this translates into measurable value: by improving BP control across populations, digital health platforms like Dario have the potential to reduce downstream cardiovascular risks, lower costs associated with complications and improve overall population health – all while integrating seamlessly with existing care workflows.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the future benefits and value of the Company's platform for employers, payers and health systems, including the potential to reduce downstream cardiovascular risks and lower costs associated with complications and improve overall population health. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com 

Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/darios-data-driven-digital-health-platform-delivers-significant-and-sustainable-improvements-in-blood-pressure-findings-published-in-jmir-cardio-302632263.html

SOURCE DarioHealth Corp.

FAQ

What did the JMIR Cardio study published Dec 4, 2025 report about DarioHealth (DRIO) and blood pressure?

The study found Dario's data-driven nudges were associated with sustained systolic BP reductions (B = –2.09; P < .001) at three months versus baseline.

How did DarioHealth's digital nudges compare to a control group in the DRIO study?

The propensity-matched control group showed a smaller systolic reduction (B = –1.06; P = .007) compared with the nudged cohort.

Did activity level affect blood pressure outcomes in the DarioHealth (DRIO) study?

Yes; users reporting higher lifestyle activity had larger systolic BP reduction (B = –5.27; P < .001).

What portion of DarioHealth clients use its cardio-metabolic suite according to the announcement?

The company reported that 59% of its clients leverage the cardio-metabolic suite to manage hypertension.

What investor impact does the DRIO study imply for employers and payers?

The announcement says improved BP control could reduce downstream cardiovascular risks and related costs for employers, payers and health systems.

When were the JMIR Cardio findings about DarioHealth's BP outcomes released?

The findings were published and announced on December 4, 2025.